Effect of Allopurinol on Clinical Outcomes in Inflammatory Bowel Disease Nonresponders to Azathioprine or 6-Mercaptopurine

Present, 1980, Treatment of Crohn’s disease with 6-mercaptopurine: a long-term, randomized, double-blind study, N Engl J Med, 302, 981, 10.1056/NEJM198005013021801

Sandborn, 2000, Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease, Cochrane Database Syst Rev

Pearson, 2000, Azathioprine for maintaining remission of Crohn’s disease, Cochrane Database Syst Rev

Sandborn, 1998, Azathioprine: state of the art in inflammatory bowel disease, Scand J Gastroenterol Suppl, 225, 92, 10.1080/003655298750027290

Dubinsky, 2000, Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease, Gastroenterology, 118, 705, 10.1016/S0016-5085(00)70140-5

Lepage, 1963, Basic biochemical effects and mechanism of action of 6-thioguanine, Cancer Res, 23, 1202

Tiede, 2003, CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes, J Clin Invest, 111, 1133, 10.1172/JCI16432

Neurath, 2005, 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn’s disease, Clin Gastroenterol Hepatol, 3, 1007, 10.1016/S1542-3565(05)00697-X

Dubinsky, 2002, 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease, Gastroenterology, 122, 904, 10.1053/gast.2002.32420

Weinshilboum, 1980, Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity, Am J Hum Genet, 32, 651

Holme, 2002, Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK, QJM, 95, 439, 10.1093/qjmed/95.7.439

Ansari, 2002, Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease, Aliment Pharmacol Ther, 16, 1743, 10.1046/j.1365-2036.2002.01353.x

Sparrow, 2005, Allopurinol safely and effectively optimizes thioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine, Aliment Pharmacol Ther, 22, 441, 10.1111/j.1365-2036.2005.02583.x

Zazgornik, 1981, Increased danger of bone marrow damage in simultaneous azathioprine-allopurinol therapy, Int J Clin Pharmacol Ther Toxicol, 19, 96

Cummins, 1996, Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation, Transplantation, 61, 1661, 10.1097/00007890-199606150-00023

Harvey, 1980, A simple index of Crohn’s-disease activity, Lancet, 1, 514, 10.1016/S0140-6736(80)92767-1

Schroeder, 1987, Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study, N Engl J Med, 317, 1625, 10.1056/NEJM198712243172603

Chocair, 1993, Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen, Lancet, 342, 83, 10.1016/0140-6736(93)91287-V

Agrawal, 2005, Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn’s disease, Clin Gastroenterol Hepatol, 3, 1215, 10.1016/S1542-3565(05)00759-7

Weyer, 2001, Human thiopurine S-methyltransferase activity in uremia and after renal transplantation, Eur J Clin Pharmacol, 57, 129, 10.1007/s002280100287

Krenitsky, 1967, Ribonucleosides of allopurinol and oxoallopurinol: isolation from human urine, enzymatic synthesis, and characterization, J Biol Chem, 242, 2675, 10.1016/S0021-9258(18)99622-5

Duley, 2005, Observations on the use of allopurinol in combination with azathioprine or mercaptopurine, Aliment Pharmacol Ther, 22, 1161, 10.1111/j.1365-2036.2005.02703.x

Duley, 2005, Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides, Ther Drug Monit, 27, 647, 10.1097/01.ftd.0000169061.52715.3e

Borges, 2002, Progress towards the discovery of xanthine oxidase inhibitors, Curr Med Chem, 9, 195, 10.2174/0929867023371229

Olah, 1994, The inhibitory effects of allopurinol on the production and cytotoxicity of tumor necrosis factor, Naunyn Schmiedebergs Arch Pharmacol, 350, 96, 10.1007/BF00180017

Dubinsky, 2003, 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients, Gastroenterology, 125, 298, 10.1016/S0016-5085(03)00938-7